Nyxoah, a Belgian medical device firm, has announced the successful completion of a $110 million funding round to drive the expansion of its sleep apnea treatment device in the United States. The company's implantable device, designed to treat obstructive sleep apnea, has shown promising results in clinical trials and is set to improve treatment options for millions of patients suffering from the condition.
Obstructive sleep apnea is a common condition that affects millions of people worldwide, causing repeated pauses in breathing during sleep, leading to fatigue, daytime sleepiness, and other complications. Nyxoah's implantable device aims to provide a long-term solution for these patients, offering a more effective and comfortable alternative to traditional treatments.
The funding round, led by new investors including funds managed by BlackRock and healthcare-focused investment firm, HBM Healthcare Investments, will enable Nyxoah to expand its US presence, strengthen its commercial operations, and continue to drive innovation in the field of sleep apnea treatment.
The company's device has already received FDA clearance in the US and has been approved for use in several European countries. With the new funding, Nyxoah plans to accelerate its US expansion, focusing on building a strong clinical and commercial presence in the market.
Nyxoah's CEO, Maxence Blin, said the funding will be instrumental in helping the company achieve its ambitious growth plans. 'This investment is a significant milestone for Nyxoah, and we are excited to have the support of such a prestigious group of investors. We believe that our implantable device has the potential to revolutionise the treatment of sleep apnea, and we are committed to making it available to patients in the US and around the world.'